OBJECTIVE: We conducted a study of minocycline to assess its safety, tolerability, and efficacy for the treatment of HIV-associated cognitive impairment. METHODS:HIV-1-infected individuals with progressive neurocognitive decline were enrolled in a double-blind, placebo-controlled study of minocycline. Participants were randomized to receive minocycline 100 mg or matching placebo orally every 12 hours. The primary efficacy measure was change in a neuropsychological test composite z score (NPZ-8) from baseline to week 24. Measures of safety included the frequency of adverse events and changes over time in laboratory tests. After 50% of participants completed the double-blind phase, an interim analysis of futility for the primary outcome measure was performed, and our Data and Safety Monitoring Board recommended early study termination. RESULTS: A total of 107 HIV-1-infected individuals with cognitive impairment were enrolled. The minocycline group did not show improvement in the primary outcome measure (NPZ-8) (mean 24-week change = 0.12) compared to placebo (mean 24-week change = 0.17) (95% confidence interval = [-0.26, 0.39], p = 0.70). There were few severe adverse events or laboratory abnormalities in either treatment group. CONCLUSION:Minocycline was safe and well-tolerated in individuals with HIV-associated cognitive impairment, but cognitive improvement was not observed. Classification of evidence. This interventional study provides Class II evidence for the safety, tolerability, and efficacy of minocycline for the treatment of HIV-associated cognitive impairment.
RCT Entities:
OBJECTIVE: We conducted a study of minocycline to assess its safety, tolerability, and efficacy for the treatment of HIV-associated cognitive impairment. METHODS:HIV-1-infected individuals with progressive neurocognitive decline were enrolled in a double-blind, placebo-controlled study of minocycline. Participants were randomized to receive minocycline 100 mg or matching placebo orally every 12 hours. The primary efficacy measure was change in a neuropsychological test composite z score (NPZ-8) from baseline to week 24. Measures of safety included the frequency of adverse events and changes over time in laboratory tests. After 50% of participants completed the double-blind phase, an interim analysis of futility for the primary outcome measure was performed, and our Data and Safety Monitoring Board recommended early study termination. RESULTS: A total of 107 HIV-1-infected individuals with cognitive impairment were enrolled. The minocycline group did not show improvement in the primary outcome measure (NPZ-8) (mean 24-week change = 0.12) compared to placebo (mean 24-week change = 0.17) (95% confidence interval = [-0.26, 0.39], p = 0.70). There were few severe adverse events or laboratory abnormalities in either treatment group. CONCLUSION:Minocycline was safe and well-tolerated in individuals with HIV-associated cognitive impairment, but cognitive improvement was not observed. Classification of evidence. This interventional study provides Class II evidence for the safety, tolerability, and efficacy of minocycline for the treatment of HIV-associated cognitive impairment.
Authors: N C Sacktor; R H Lyles; R L Skolasky; D E Anderson; J C McArthur; G McFarlane; O A Selnes; J T Becker; B Cohen; J Wesch; E N Miller Journal: Neurology Date: 1999-05-12 Impact factor: 9.910
Authors: Ned C Sacktor; Matthew Wong; Noeline Nakasujja; Richard L Skolasky; Ola A Selnes; Seggane Musisi; Kevin Robertson; Justin C McArthur; Allan Ronald; Elly Katabira Journal: AIDS Date: 2005-09-02 Impact factor: 4.177
Authors: Paul H Gordon; Dan H Moore; Robert G Miller; Julaine M Florence; Joseph L Verheijde; Carolyn Doorish; Joan F Hilton; G Mark Spitalny; Robert B MacArthur; Hiroshi Mitsumoto; Hans E Neville; Kevin Boylan; Tahseen Mozaffar; Jerry M Belsh; John Ravits; Richard S Bedlack; Michael C Graves; Leo F McCluskey; Richard J Barohn; Rup Tandan Journal: Lancet Neurol Date: 2007-11-05 Impact factor: 44.182
Authors: Yunyan Zhang; Luanne M Metz; V Wee Yong; Robert B Bell; Michael Yeung; David G Patry; J Ross Mitchell Journal: Can J Neurol Sci Date: 2008-05 Impact factor: 2.104
Authors: Richard A Zuckerman; Aldo Lucchetti; William L H Whittington; Jorge Sanchez; Robert W Coombs; Rosario Zuñiga; Amalia S Magaret; Anna Wald; Lawrence Corey; Connie Celum Journal: J Infect Dis Date: 2007-10-31 Impact factor: 5.226
Authors: G Schifitto; J Zhang; S R Evans; N Sacktor; D Simpson; L L Millar; V L Hung; E N Miller; E Smith; R J Ellis; V Valcour; E Singer; C M Marra; D Kolson; J Weihe; R Remmel; D Katzenstein; D B Clifford Journal: Neurology Date: 2007-07-25 Impact factor: 9.910
Authors: Scott Letendre; Jennifer Marquie-Beck; Edmund Capparelli; Brookie Best; David Clifford; Ann C Collier; Benjamin B Gelman; Justin C McArthur; J Allen McCutchan; Susan Morgello; David Simpson; Igor Grant; Ronald J Ellis Journal: Arch Neurol Date: 2008-01
Authors: Y Lampl; M Boaz; R Gilad; M Lorberboym; R Dabby; A Rapoport; M Anca-Hershkowitz; M Sadeh Journal: Neurology Date: 2007-10-02 Impact factor: 9.910
Authors: Kelly A Meulendyke; Ceereena Ubaida-Mohien; Julia L Drewes; Zhaohao Liao; Lucio Gama; Kenneth W Witwer; David R Graham; M Christine Zink Journal: J Infect Dis Date: 2014-03-31 Impact factor: 5.226
Authors: Joshua A Walker; Andrew D Miller; Tricia H Burdo; Michael S McGrath; Kenneth C Williams Journal: J Acquir Immune Defic Syndr Date: 2017-04-15 Impact factor: 3.731
Authors: Ned Sacktor; Sachiko Miyahara; Scott Evans; Giovanni Schifitto; Bruce Cohen; Norman Haughey; Julia L Drewes; David Graham; M Christine Zink; Caroline Anderson; Avindra Nath; Carlos A Pardo; Sean McCarthy; Lara Hosey; David Clifford Journal: J Neurovirol Date: 2014-11-07 Impact factor: 2.643
Authors: Shiping Zou; Joyce M Balinang; Jason J Paris; Kurt F Hauser; Babette Fuss; Pamela E Knapp Journal: J Neurochem Date: 2019-03-15 Impact factor: 5.372
Authors: Albert M Anderson; Jeffrey L Lennox; Mark M Mulligan; David W Loring; Henrik Zetterberg; Kaj Blennow; Cari Kessing; Rajeth Koneru; Kirk Easley; William R Tyor Journal: J Neurovirol Date: 2016-07-11 Impact factor: 2.643